Skip to main content

Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move

The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's safety and efficacy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.